Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial | MicrobiomeTrials← Back to trialsNCT07847710
Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-09-30Est. Completion: 2028-03-01
Enrollment target: 81 participants Locations- The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Other microbiome trials you might be interested in
Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, ChinaEst. completion Jan 2030
Resectable Intrahepatic Cholangiocarcinoma
Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and surviv…
Rennes, FranceEst. completion Sep 4, 2027